相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise
Daphne Morel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Principles and mechanisms of non-genetic resistance in cancer
Charles C. Bell et al.
BRITISH JOURNAL OF CANCER (2020)
Editor's Note: p38 Mitogen-activated Protein Kinase Pathway Suppresses Cell Survival by Inducing Dephosphorylation of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase1,2
Song-Ping Li et al.
CANCER RESEARCH (2020)
Targeting the ERK Signaling Pathway in Melanoma
Paola Savoia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
Romi Gupta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas
Ophelia Maertens et al.
CANCER DISCOVERY (2019)
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy
Michael F. Emmons et al.
CANCER RESEARCH (2019)
Inhibition of glucose metabolism through treatment of BRAF mutated metastatic melanoma with vemurafenib.
Govind Warrier et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Min-Wu Chao et al.
CLINICAL EPIGENETICS (2019)
Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
Stephen A. Luebker et al.
FRONTIERS IN ONCOLOGY (2019)
Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer
Srinivas Patnaik et al.
FRONTIERS IN PHARMACOLOGY (2019)
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Mehwish Khaliq et al.
CANCERS (2019)
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Zhan Yao et al.
NATURE MEDICINE (2019)
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
ONECUT2 is a driver of neuroendocrine prostate cancer
Haiyang Guo et al.
NATURE COMMUNICATIONS (2019)
USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer
Robyn Laura Kosinsky et al.
CELL DEATH & DISEASE (2019)
ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression
Qingyang Ma et al.
SCIENTIFIC REPORTS (2019)
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies
William W. Feng et al.
CELL REPORTS (2019)
Targeting Epigenetics in Cancer
Richard L. Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Targeting FBPase is an emerging novel approach for cancer therapy
Gao-Min Liu et al.
CANCER CELL INTERNATIONAL (2018)
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow et al.
CELL (2018)
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Liqin Wang et al.
CELL (2018)
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
Zheng Xue et al.
CELL RESEARCH (2018)
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer
Rasmi R. Mishra et al.
CLINICAL CANCER RESEARCH (2018)
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Mohd Wahid et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Jaquelyn N. Sanchez et al.
DRUGS (2018)
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
Ileabett M. Echevarria-Vargas et al.
EMBO MOLECULAR MEDICINE (2018)
Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors
Elnaz Faghfuri et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma
Shomereeta Roy et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2018)
Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours
Javier Garcia-Bermudez et al.
NATURE CELL BIOLOGY (2018)
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Andrew M. Kidger et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Cancer epigenetics: Moving forward
Angela Nebbioso et al.
PLOS GENETICS (2018)
The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation
Nomeda Girnius et al.
ELIFE (2018)
Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling
Oleksii S. Rukhlenko et al.
CELL SYSTEMS (2018)
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
Yiu To Yeung et al.
EBIOMEDICINE (2018)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Amila Suraweera et al.
FRONTIERS IN ONCOLOGY (2018)
Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway
Ping Yang et al.
CANCER LETTERS (2018)
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
Hiroki Sato et al.
CANCER SCIENCE (2018)
Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis
Jacob Insua-Rodriguez et al.
EMBO MOLECULAR MEDICINE (2018)
Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells
Xiaolu Han et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
Sabrina Rizzolio et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Francesca Zanconato et al.
NATURE MEDICINE (2018)
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
Thomas Strub et al.
NATURE COMMUNICATIONS (2018)
AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel
Masahiro Yamamoto et al.
ANTICANCER RESEARCH (2018)
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
Mirja Rotinen et al.
NATURE MEDICINE (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
Tonci Sustic et al.
GENOME MEDICINE (2018)
Epigenetic mechanisms as a new approach in cancer treatment: An updated review
Masoumeh Fardi et al.
GENES & DISEASES (2018)
Mathematical modeling and computational prediction of cancer drug resistance
Xiaoqiang Sun et al.
BRIEFINGS IN BIOINFORMATICS (2018)
The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Yufang Ma et al.
CLINICAL CANCER RESEARCH (2017)
MEK inhibitors in oncology: a patent review (2015-Present)
Debarshi Kar Mahapatra et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development
Nivedita M. Ratnam et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells
Xiaomin Feng et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors
Caner Saygin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
Giulia Cesi et al.
MOLECULAR CANCER (2017)
Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells
Kayleigh C. Ross et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation
Ting Zhao et al.
MOLECULAR MEDICINE REPORTS (2017)
Rare cell variability and drug- induced reprogramming as a mode of cancer drug resistance
Sydney M. Shaffer et al.
NATURE (2017)
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Hezhe Lu et al.
NATURE (2017)
A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Gao Guo et al.
NATURE NEUROSCIENCE (2017)
Targeting the unfolded protein response in cancer
Rani Ojha et al.
PHARMACOLOGICAL RESEARCH (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
Serine and Functional Metabolites in Cancer
Alice C. Newman et al.
TRENDS IN CELL BIOLOGY (2017)
Distinct histone modifications denote early stress-induced drug tolerance in cancer
Abdullah Al Emran et al.
Oncotarget (2017)
Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer
Yonglei Liu et al.
ONCOTARGET (2017)
Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
Keisha N. Hardeman et al.
SCIENTIFIC REPORTS (2017)
Role of the unfolded protein response in tumor cell characteristics and cancer outcome
Antoine Galmiche et al.
CURRENT OPINION IN ONCOLOGY (2017)
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer
Nuria Eritja et al.
AUTOPHAGY (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Hiroyuki Ozawa et al.
CLINICAL CANCER RESEARCH (2017)
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction
Xin Jin et al.
CANCER RESEARCH (2017)
Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy
N. D. Amoedo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2017)
Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells
Li Xu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)
Neelima Vidulal et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation
Pablo G. Jambrina et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Franziska Baenke et al.
MOLECULAR ONCOLOGY (2016)
Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel
Manabu Seino et al.
ONCOLOGY REPORTS (2016)
Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals
Hongjun Xie et al.
ONCOTARGET (2016)
Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway
Kang Qi et al.
ANTI-CANCER DRUGS (2016)
Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin
Yi-Te Lin et al.
BIOCHEMICAL PHARMACOLOGY (2016)
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
Taru Muranen et al.
CANCER RESEARCH (2016)
Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-
Eva Martini et al.
CELL CYCLE (2016)
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships
Andras Zeke et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2016)
c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
Raul Rincon et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Tumour-specific proline vulnerability uncovered by differential ribosome codon reading
Fabricio Loayza-Puch et al.
NATURE (2016)
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
Haiyang Guo et al.
NATURE GENETICS (2016)
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Andrew P. Feinberg et al.
NATURE REVIEWS GENETICS (2016)
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
A. N. Paranjape et al.
ONCOGENE (2016)
Integrating network reconstruction with mechanistic modeling to predict cancer therapies
Melinda Halasz et al.
Science Signaling (2016)
The Warburg Effect: How Does it Benefit Cancer Cells?
Maria V. Liberti et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
Ying-Ying Li et al.
ONCOTARGET (2016)
Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
Samuel Goncalves-Ribeiro et al.
ONCOTARGET (2016)
The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer
Chia-Lin Liu et al.
ONCOTARGET (2016)
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells
Shin-Hyung Park et al.
ONCOTARGET (2016)
Integrating network reconstruction with mechanistic modeling to predict cancer therapies
Melinda Halasz et al.
Science Signaling (2016)
BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma
Luca Paoluzzi et al.
CANCER MEDICINE (2016)
Natural course and biology of CML
Bradley Chereda et al.
ANNALS OF HEMATOLOGY (2015)
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
Samuel W. Brady et al.
CANCER BIOLOGY & THERAPY (2015)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
The Stress Kinase p38α as a Target for Cancer Therapy
Ana Igea et al.
CANCER RESEARCH (2015)
Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
Francisco Azuaje et al.
CELL COMMUNICATION AND SIGNALING (2015)
HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Robbie Carson et al.
CLINICAL CANCER RESEARCH (2015)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2015)
The Warburg effect: Evolving interpretations of an established concept
Xiaozhuo Chen et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases
Ankit Kumar et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas
Jinhua Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15
Hong Ji et al.
MOLECULAR MEDICINE REPORTS (2015)
Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis
Mohammad Fallahi-Sichani et al.
MOLECULAR SYSTEMS BIOLOGY (2015)
IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance
Xiao-Lei Ye et al.
ONCOLOGY REPORTS (2015)
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Pui-Kei Wu et al.
SEMINARS IN ONCOLOGY (2015)
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Zhen Ning Wee et al.
NATURE COMMUNICATIONS (2015)
Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib
Zhe Li et al.
THORACIC CANCER (2015)
Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects
Boris N. Kholodenko
CELL REPORTS (2015)
PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer
Yanjie Zhang et al.
EBIOMEDICINE (2015)
The dynamic control of signal transduction networks in cancer cells
Walter Kolch et al.
NATURE REVIEWS CANCER (2015)
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Thuy V. Nguyen et al.
BIOMATERIALS (2014)
JNK signalling in cancer: in need of new, smarter therapeutic targets
Concetta Bubici et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
RANK expression on breast cancer cells promotes skeletal metastasis
Michelle L. Blake et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
Rizwan Haq et al.
CLINICAL CANCER RESEARCH (2014)
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Hariharan Easwaran et al.
MOLECULAR CELL (2014)
SAICAR Induces Protein Kinase Activity of PKM2 that Is Necessary for Sustained Proliferative Signaling of Cancer Cells
Kirstie E. Keller et al.
MOLECULAR CELL (2014)
Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
Jelena Urosevic et al.
NATURE CELL BIOLOGY (2014)
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
D. Wetterskog et al.
ONCOGENE (2014)
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
Guangyuan Li et al.
PLOS ONE (2014)
Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade
Xuefeng Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
Valentina Grossi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
Tiffany J. Parmenter et al.
CANCER DISCOVERY (2014)
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Elza C. de Bruin et al.
CANCER DISCOVERY (2014)
Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
Masashi Okada et al.
ONCOTARGET (2014)
Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition
Qiong Wang et al.
ONCOTARGET (2014)
被撤回的出版物: JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy (Retracted article. See vol. 11, 2021)
Xinbing Sui et al.
SCIENTIFIC REPORTS (2014)
Poised epigenetic states and acquired drug resistance in cancer
Robert Brown et al.
NATURE REVIEWS CANCER (2014)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield et al.
NATURE REVIEWS CANCER (2014)
PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress
Francisca Vazquez et al.
CANCER CELL (2013)
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch et al.
CANCER CELL (2013)
In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors
Kevin J. Basile et al.
CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
S.M. Donnelly et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Epigenetic Reprogramming in Cancer
Mario L. Suva et al.
SCIENCE (2013)
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
M. R. Milone et al.
CELL DEATH & DISEASE (2013)
Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation
A. Notte et al.
CELL DEATH & DISEASE (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Roles of p38 MAPKs in invasion and metastasis
Ivan del Barco Barrantes et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
Jueng Soo You et al.
CANCER CELL (2012)
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Patrick S. Ward et al.
CANCER CELL (2012)
HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway
Y. Yao et al.
CANCER GENE THERAPY (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Quercetin Suppresses Drug-Resistant Spheres via the p38 MAPK-Hsp27 Apoptotic Pathway in Oral Cancer Cells
Su-Feng Chen et al.
PLOS ONE (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Computational Approaches for Analyzing Information Flow in Biological Networks
Boris Kholodenko et al.
SCIENCE SIGNALING (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
Davide Torti et al.
EMBO MOLECULAR MEDICINE (2011)
The role of JNK in the development of hepatocellular carcinoma
Madhumita Das et al.
GENES & DEVELOPMENT (2011)
Mitochondrial Localization and Regulation of BRAF(V600E) in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAF(V600E)
Min Hee Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Craig J. Ceol et al.
NATURE (2011)
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression
Daniel Schramek et al.
NATURE GENETICS (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A decade of exploring the cancer epigenome - biological and translational implications
Stephen B. Baylin et al.
NATURE REVIEWS CANCER (2011)
Mechanisms and functions of p38 MAPK signalling
Ana Cuadrado et al.
BIOCHEMICAL JOURNAL (2010)
Pathological roles of MAPK signaling pathways in human diseases
Eun Kyung Kim et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer
Katherine G. Finegan et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
Oliver E. Sturm et al.
SCIENCE SIGNALING (2010)
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib
Disha Dumka et al.
LEUKEMIA & LYMPHOMA (2009)
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Jihye Yun et al.
SCIENCE (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice
Wataru Shibata et al.
CANCER RESEARCH (2008)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Suleiman Massarweh et al.
CANCER RESEARCH (2008)
The complexity of mitogen-activated protein kinases (MAPKs) made simple
M. Krishna et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe et al.
CLINICAL CANCER RESEARCH (2008)
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation
Lijian Hui et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
Reidun Aesoy et al.
MOLECULAR CANCER RESEARCH (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Javier A. Menendez et al.
NATURE REVIEWS CANCER (2007)
p38α suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway
Lijian Hui et al.
NATURE GENETICS (2007)
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles
Priti S. Hegde et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Interfering with MAP kinase docking interactions - Implications and perspective for the p38 route
Federico Mayor et al.
CELL CYCLE (2007)
p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis
Ignacio Dolado et al.
CANCER CELL (2007)
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
OM Grbovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells
B Nicke et al.
MOLECULAR CELL (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells
S Parmar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
P38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor
XM Qi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence
WP Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
分享论文
